glipizide

17 Nov: Is Januvia worth the price?

The Type 2 diabetes drug Januvia (sitagliptin) has become a source of controversy after the drug’s maker, Merck, funded a letter to doctors by CVS Caremark, the pharmacy benefits manager, urging the physicians to add the drug to specific patients’ treatment regimens. Januvia costs as much as 10 times the price of older diabetes drugs such as metformin and glipizide xl. (Note: Januvia purchased from a Canadian pharmacy costs about half as much as from a U.S. pharmacy — though it is still significantly more expensive than metformin and glipizide.) Beyond the apparent conflict of interest in CVS Caremark’s letter, the question most important to patients is whether Januvia’s superiority over older, cheaper diabetes drugs makes it worth the additional…